Cargando…
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide ca...
Ejemplares similares
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
por: Zabana, Yamile, et al.
Publicado: (2022) -
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
por: Riestra, Sabino, et al.
Publicado: (2022) -
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study
por: Guerra, Ivan, et al.
Publicado: (2023) -
Validity of a Single-Factor Model Underlying the Metabolic Syndrome in Children: A confirmatory factor analysis
por: Martínez-Vizcaíno, Vicente, et al.
Publicado: (2010) -
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
por: Cañete, Fiorella, et al.
Publicado: (2020)